CD274 and neoplasm: Certain biomarkers, such as programmed cell death-ligand 1 (PD-L1), tumor mutational burden (TMB), and neoantigen load, which may reflect the state of tumor immune microenvironment, have shown utilities in selecting patients who are likely to benefit from ICIs treatment.